Medivir AB (LTS:0GP7) Marketable Securities : kr147.50 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Medivir AB Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Medivir AB's Marketable Securities for the quarter that ended in Mar. 2024 was kr147.50 Mil.

Medivir AB's annual Marketable Securities declined from Dec. 2021 (kr206.48 Mil) to Dec. 2022 (kr110.99 Mil) but then increased from Dec. 2022 (kr110.99 Mil) to Dec. 2023 (kr143.96 Mil).

Medivir AB Marketable Securities Historical Data

The historical data trend for Medivir AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Marketable Securities Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

100.21

55.97

206.48

110.99

143.96

Medivir AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															95.90	76.50	54.20	143.96	147.50

Medivir AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Medivir AB (LTS:0GP7) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Medivir AB Marketable Securities Related Terms

Thank you for viewing the detailed overview of Medivir AB's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (LTS:0GP7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines